Fibrin clot properties and fibrinolysis in patients with endocrine hypertension due to aldosterone or catecholamines excess.
fibrin clot structure
fibrinolysis
hyperaldosteronism
hypertension
pheochromocytoma/paranganglioma
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
12
10
2021
received:
04
08
2021
accepted:
30
10
2021
pubmed:
16
11
2021
medline:
28
1
2022
entrez:
15
11
2021
Statut:
ppublish
Résumé
The aim of the study was to investigate a new possible background of increased risk of cardiovascular events in two forms of endocrine hypertension: in primary aldosteronism (PA) and pheochromocytoma/paraganglioma (PPGL) in comparison to essential hypertension (EHT). Prothrombotic properties of the fibrin clot structure, impaired fibrinolysis and enhanced thrombin generation have been reported to be associated with increased cardiovascular risk. Patients with PA and PPGL were evaluated at baseline and re-evaluated 3 months after causative treatment. At baseline PA and PPGL patients were compared to matched EHT patients and to healthy controls. The study included 35 patients with PA, 16 patients with PPGL and two reference groups of patients with EHT (32 and 22 patients) and healthy controls (35 and 23 subjects). All subjects underwent evaluation according to the study protocol that included plasma fibrin clot permeability (Ks), clot lysis time, endogenous thrombin potential. There were no differences in clot structure and fibrinolytic activity in PA and PPGL patients as compared to matched patients with EHT, whereas all hypertensive groups were characterized by more compact fibrin clot structure, faster clot formation and enhanced thrombin generation in comparison to healthy controls. Both in PA and PPGL patients, fibrin clot properties and fibrinolytic parameters remained stable after the causative treatment. Patients with PA and PPGL are at a prothrombic state comparable to patients with EHT. The results suggest the higher risk of cardiovascular events observed in hypertensive PA and PPGL as compared to EHT is not mediated through investigated prothrombic mechanisms.
Substances chimiques
Catecholamines
0
Aldosterone
4964P6T9RB
Fibrin
9001-31-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
114-122Subventions
Organisme : National Centre of Science, Cracow, Poland
ID : 2013/11/N/NZ5/03740
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Prejbisz A, Warchol-Celinska E, Lenders JW, Januszewicz A. Cardiovascular risk in primary hyperaldosteronism. Horm Metab Res. 2015;47:973-980.
Wu X, Yu J, Tian H. Cardiovascular risk in primary aldosteronism: a systematic review and meta-analysis. Medicine. 2019;98:e15985.
Crona J, Taieb D, Pacak K. New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr Rev. 2017;38:489-515.
Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. J Hypertens. 2011;29:2049-2060.
Zabczyk M, Undas A. Plasma fibrin clot structure and thromboembolism: clinical implications. Pol Arch Intern Med. 2017;12:873-881.
Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006;26:2567-2573.
Undas A, Szuldrzynski K, Stepien E, et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis. 2008;196:551-557.
Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res. 2010;125:357-361.
Zabczyk M, Majewsk J, Lelakowski J. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation Pol. Arch Intern Med. 2011;11:400-407.
Bagoly Z. Altered fibrin clot phenotype as predictor of the risk of recurrent venous thromboembolism: evidence is growing. Pol Arch Intern Med. 2018;10:569-571.
Jozwik-Plebanek K, Prejbisz A, Wypasek E, et al. Altered plasma fibrin clot properties in hypertensive patients with obstructive sleep apnoea are improved by continuous positive airway pressure treatment. J Hypertens. 2017;35:1035-1043.
Milliez P, Girerd X, Plouin PF. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248.
Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:1889-1916.
Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99:1915-1942.
Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5:689-699.
Eisenhofer G, Klink B, Richter S, Lenders JW, Robledo M. Metabologenomics of phaeochromocytoma and paraganglioma: an integrated approach for personalised biochemical and genetic testing. Clin Biochem Rev. 2017;38:69-100.
Eisenhofer G, Peitzsch M, Kaden D, et al Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. Clin Chim Acta. 2019;490:46-54.
Monticone S, Ascenzo D, Moretti F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41-50.
P M Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993;87:1969-1973.
Oikawa T, Freeman M, Lo W. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 1997;51:164-172.
Brown NJ, Agirbasli MA, Williams GH. Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1 in humans. Hypertension. 1998;32:965-971.
Sechi LA, Novello M, Colussi G, et al. Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage. Am J Hypertens. 2008;21:1347-1353.
Brown NJ, Nakamura S, Ma L, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000;58:1219-1227.
Sang M, Fu Y, Wei C, et al. Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary aldosteronism and essential hypertension. J Renin Angiotensin Aldosterone Syst. 2021;22:1470320321999491. doi:10.1177/1470320321999491
Petrak O, Widimisky Jr. J, Zelinka T, et al. Biochemical markers of endothelial dysfunction in patients with endocrine and essential hypertension. Physiol Res. 2006;55:597-602.
Squizzato A, Gerdes VE, Ageno W, Buller HR. The coagulation system in endocrine disorders: a narrative review. Intern Emerg Med. 2007;2:76-83.
Vosburgh CH, Richards AN. An experimental study of the sugar content and extra vascular coagulation of the blood after administration of adrenalin. Am J Physiol. 1903;9:35-51.
Biggs R, MacFarlane RG, Philling J. Observations on fibrinolysis; experimental activity produced by exercise or adrenaline. Lancet. 1947;1:402-405.
Ingram GIC. Increase in antihemophilic globulin activity following infusion of adrenaline. J Physiol. 1961;156:217-224.
Grant PJ. Hormonal regulation of the acute haemostatic response to stress. Blood Coagul Fibrinolysis. 1990;1:299-306.
Elias A, Rock W, Odetalla A, et al. Enhanced thrombin generation in patients with arterial hypertension. Thromb Res. 2019;174:121-128.
Varughese G. Is hypertension a prothrombic state? Curr Hypertens Rep. 2005;7:168-173.